If no one ever took risks, Michelangelo would have painted the Sistine floor.
Ident ification of proteins unique to cancer cells and generation of antibodies (Abs) binding to them have led to improved management for non-Hodgkin's lymphoma (NHL). Monoclonal Ab (mAb) Lym-1, an attractive carrier of radioisotopes for imaging and therapy, binds to a human leukocyte antigen DR (HLA-DR) protein variant (1) . HLA-DR has characteristics in common with other B-cell-surface antigens-for example, CD20-that make it an excellent target; disparate characteristics make it even more attractive. The basal level of HLA-DR expression on malignant B-cells is about 100 times more than that on normal B-cells (2, 3) , so that only small amounts of Lym-1 Ab are needed to target extravascular malignant lymphoma (4, 5) .
However, Abs are macromolecules that penetrate poorly and interact with a variety of Fc receptors, thereby limiting their selectivity as radioisotope carriers and adding to their adverse event profile. Furthermore, the immunogenicity of Ab-based reagents can be minimized, but not eliminated, using ''humanized'' Abs (6) (7) (8) (9) (10) . In silico molecular modeling enables the design of small, multidentate molecules to bind to proteins. The mode of binding of these molecules mimics the specific, high-affinity interactions achieved through the formation of multiple contacts between residues on the surfaces of an Ab and its target (11) (12) (13) (14) .
Although the development of multidentate high-affinity, target-specific ligands is a proven technology, it has not yet been widely applied to cancer imaging and therapy. We have characterized the Lym-1 epitope on HLA-DR, identified unique structural features within its epitope, and have developed a new class of small molecules-selective high-affinity ligands (SHALs)-to bind to malignant lymphocytes for molecular imaging and therapy. Linking together 2 ligands, each of which binds weakly to a protein and exhibits only modest selectivity, provides a molecule that binds to its target more tightly and with high selectivity (11) (12) (13) (14) . A series of bidentate ''Ab mimics'' for the epitopic region to which Lym-1 Ab binds to HLA-DR has been synthesized, using pairs of ligands shown to bind to sites within the Lym-1 epitopic region. These bidentate SHALs bind selectively to cultured human lymphoma cells with near-nanomolar affinity. They also bind to human NHL tissue, compete for binding with Lym-1, and do not bind to plasma proteins and other malignant cells that lack HLA-DR10 (15, 16) . Because SHALs are much smaller than antibodies, these results suggest that SHALs can improve the imaging contrast and therapeutic index for NHL.
When compared with biologicals-for example, Abs and peptides-SHALs can be synthesized inexpensively in large amounts from commercially available components, have a long shelf life, and can be used in their initial form or as a precursor for creating more sophisticated targeting molecules. Here, we describe the pharmacokinetics and tissue biodistribution, in NHL xenografted mice, of a series of firstgeneration SHALs and the lessons learned that apply to their future development for molecular imaging and therapy.
MATERIALS AND METHODS

Mouse Model
Raji cells, human Burkitt's lymphoma cells obtained from the American Type Culture Collection (ATCC), were grown in RPMI 1640 and supplemented as recommended by the ATCC. Female athymic BALB/c nu/nu mice (Harlan Sprague-Dawley) were maintained according to the University of California animal care guidelines on a normal diet ad lib. At 6 wk of age, the mice received 4 Gy (400 rad) of external beam irradiation to suppress immune response to the Raji xenografts; 3-5 d later, Raji cells (6 · 10 6 ) were injected subcutaneously on the abdomen of the mice. Implants grown 3 wk were measured in 3 orthogonal dimensions using a caliper; tumor volume was calculated using the formula for hemiellipsoids (17) . At the time of SHAL injection, xenografts were well established. Mice with tumor volumes of 50-500 mm 3 were used to evaluate the pharmacokinetics (17) . A total of 112 mice were included in this study; there were between 20 and 42 mice in each group.
SHAL Design and Chemistry
Design. Computational docking was used to identify ligands that bind to either of 2 sites within the Lym-1 epitopic region. A program (SPHGEN) was used to identify potential ligand-binding sites on the surface of HLA-DR10 protein (18, 19) ; 3 unique sites were identified within the Lym-1 epitopic region. On the basis of their proximity to each other, the uniqueness of amino acid residues lining each site, and their location within the Lym-1 Ab region of FIGURE 1. Chemical structures in 2 dimensions, and acronyms (in parentheses), for ligands used to generate SHALs.
the HLA-DR protein, the 2 best sites were selected for virtual screening of the Available Chemicals Directory ([ACD] Molecular Design Limited, Inc.). Combinations of 2 ligands that were verified by nuclear magnetic resonance spectroscopy and surface plasmon resonance to bind to HLA-DR10 were used to synthesize SHALs.
Synthesis. SHALs to bind HLA-DR10, and related HLA-DRs, were synthesized using an orthogonally protected lysine residue of a solid-phase chlorotrityl chloride resin (16, 20) . All SHALs were based on a parent lysine molecule covalently bonded to various ligands. Briefly, the SHALs were synthesized by linking a site-1 ligand with a site-2 ligand using a lysine(L)-PEG(P)-based linker (PEG is polyethylene glycol) and a solid, polymer-supported synthesis on chlorotrityl chloride resin, as described (20) . All of the ligands had carboxyl groups for ready conjugation to the amino groups on lysine. The ligand combinations used to synthesize SHALs were deoxycholate and leuenkephalin, deoxycholate and triiodothyronine, deoxycholate and thyronine, and dabsylvaline and N-benzoyl-L-arginyl-4-aminobenzoic acid (Fig. 1 ). SHALs were synthesized with 0, 1, or 2 short PEG linkers between the ligands to assess the effect of linker length.
The e-amino group of the lysine was used to attach a biotin or 1,4,7,10-tetraazacyclododecane-N,N9,N$,N%-tetraacetic acid (DOTA) chelate. Conversion to DOTA (or biotinylated) SHAL derivatives was accomplished by dissolving the SHALs in 500 mL anhydrous N,N-dimethylformamide (DMF) and 100 mL diisopropylethylamine. The biontinyl-OSu (341.39 g/mol, 1.1 eq) or hexafluorophosphate salt of DOTA N-hydroxy-succinimide ester (933.36 g/mol, 0.95-1.1 eq) was added to the mixture as a solid. The reaction was gently mixed for 15 min and monitored by analytic high-performance liquid chromatography (HPLC). On completion, the reaction solution was diluted with 300 mL H 2 O and 300 mL acetonitrile, both containing 1% trifluoroacetic acid (TFA) and HPLC purified into two 600-mL aliquots. Purified, lyophilized DOTA-SHALs were analyzed by HPLC and electrospray ionization mass spectrometry (ESI-MS).
The acronym for each SHAL consists of a 1-or 2-letter code for the ligand, with lysine and PEG designated as L and P, respectively, and DOTA and biotin designated as Do and B, respectively. Examples of SHALs that have been synthesized and their corresponding identity and acronyms are shown in (Table 1 ; Fig. 2 ). SHALs were purified using reverse-phase (RP) HPLC. Analytic HPLC was performed at 1 mL/min on an Agilent 1100 instrument using a Waters Symmetry C18, 5 mm, 4.2 · 150 mm column, and semipreparative HPLC was performed at 10 mL/min on a Waters Symmetryprep C18, 7 mm, 19 · 300 mm column. Both HPLC methods used a linear gradient from 95% H 2 O (1% TFA) to 80% MeCN (1% TFA) over 12 min and a diode array for detection. SHALs were characterized using proton and carbon NMR spectroscopy and ESI-MS; all SHALs were found to have molecular weights within 0.07% of their theoretical molecular weight.
Radiochemistry. To determine the fraction of DOTAs available for metal chelation, each SHAL preparation was titrated using a cobalt assay (21) . The concentration of the unchelated DOTA-SHAL was estimated using the HPLC peak area ultraviolet absorbance at 254 nm. An aqueous solution of 57 CoCl 2 , calibrated by the manufacturer, was added to an aliquot of DOTA-SHAL in 10% dimethyl sulfoxide (DMSO) in phosphate-buffered saline (PBS) diluted in 0.1 M NH 4 OAc, pH 5.3. This mixture was adjusted to pH 7 using NH 4 OAc and held for 30 min at room temperature; ethylenediaminetetraacetic acid (EDTA; 0.1 M) was added to the reaction mixture, which was incubated for 15 min to sequester nonspecifically bound and excess cobalt ions. 57 Co-DOTA-SHAL was separated using thin-layer chromatography (TLC) and precoated silica gel plates with 10% aqueous NH 4 OAc/MeOH (1:1, v/v) as the eluent, and the concentration was determined by radiation counting using a 1282 CompuGamma CS Gamma Counter against a known quantity of the calibrated 57 CoCl 2 solution. The metal chelatable DOTA was calculated as the ratio of the molar concentration of the 57 Co-DOTA-SHAL chelate and the amount of DOTA-SHAL; this ratio ranged from 50% to 60% (Table 2) .
DOTA-SHALs were labeled with carrier-free 111 InCl 3 (MDS Nordion) using the following method (20) . An aliquot of 111 InCl 3 (15-20 mL) was added to a solution of DOTA-SHAL (25-50 mg) in 0.1 M NH 4 OAc, pH 5.3 (50 mL); the final pH of the reaction mixture was adjusted to 6.5 by adding 4 M NH 4 OAc, and the mixture was incubated for 1 h at 37°C. Then 0.1 M EDTA (10-20 mL) 31 . The radiolabeled product was purified using HPLC, followed by dialysis in PBS with a 1-kDa cutoff membrane. The purity of the radiolabeled SHALs was determined by TLC (10% NH 4 OAc/MeOH, 1:1), HPLC, and cellulose acetate electrophoresis (CAE). CAE resolved 111 In-DOTA-SHALs and 111 In-EDTA; radioactive peaks were observed at 2.3-3.0 cm and .6.5 cm, respectively. Similar results were observed in the TLC assay; 111 In-DOTA-SHALs showed little migration from the point of application (R f 5 0.25-0.3), whereas 111 In-EDTA moved toward the solvent front (R f 5 0.5). By HPLC, 111 In-EDTA eluted at 2.5-3.0 mL and 111 In-DOTA-SHALs eluted at 9.5-10 mL. The 111 In labeled SHALs were purified using RP-HPLC (Fig. 3) or a 1-kDa dialysis membrane in PBS and concentrated using a Savant Speedvac SC110 (Thermo Fisher Scientific, Inc.). Final radiochemical purity was determined using C18 RP-TLC (DC-Plastikfolien kieselgel 60 F254; EM Science), HPLC, and CAE. The final product was dissolved in 10% DMSO in PBS and proved to be stable over 72 h at room temperature.
Study Design
Four bidentate 111 In-DOTA-SHALs (LeacPLDDo, ItPLDDo, DvLPTPLDo, and DvLPBaPLDo) were studied in mice at 2 doses, 
Pharmacokinetics
The pharmacokinetics for each of the 4 SHALs were evaluated using serial biodistribution, WBAR, and blood studies. In groups of mice, each SHAL was injected into the tail vein in mass amounts of 1 or 20 mg for biodistribution and 20 mg for WBAR studies-1.1-1.9 MBq (30-50 mCi) and 7.4-11.1 MBq (200-300 mCi), respectively. Methods for obtaining pharmacokinetic data using 111 In have been described (22) . The 111 In dose was measured using a CRC-12 dose calibrator (Capintec, Inc.) and was confirmed by counting the mouse immediately after injection, with 2 opposed, isoresponsive sodium iodide detectors (Picker Nuclear) calibrated for volume and geometry. Decay-corrected radioactivity was expressed as the percentage injected dose (%ID) and %ID/mL or %ID/g, respectively. To determine whole-body clearances, mice were counted immediately and serially after injection using the isoresponsive sodium iodide detector system; blood clearances were determined by collecting blood samples (2 mL
These data over time were best fit to a monoexponential function. Pharmacokinetic data for other tissues were obtained by sacrificing mice at 2, 4, and 24 h after injection, removing and weighing the tissues, and counting them in the same g-well counter. Using standards of comparable volume and geometry, the concentration in each sample was expressed as %ID/g. WBAR was conducted as previously described (23) . Mice were anesthetized using an intravenous injection of 60 mg/100 mL aqueous solution of sodium pentobarbital, which then were flash frozen in a hexane, dry ice bath. The frozen mice were embedded in 4% carboxymethylcellulose, and sagittal sections were generated with a Leica Polycut at 220°C. Sections of 50-mm thickness were obtained to show tumors, spleen, kidney, liver, and the midline of the vertebral column. Radiographs of the sections were prepared by exposing the sections to x-ray film (BioMax MS; Kodak).
Statistical Analysis
Data are reported as mean 6 SD. Statistical comparisons were based on the Wilcoxon rank sum test (24), a procedure based on ranking the values of 2 test groups. Differences were considered statistically significant if P values # 0.05. Clearances were assessed using least-mean-square linear regression analyses of the %ID versus time for monoexponential and biexponential fits. Additionally, monoexponential fits for all mice in a group and only the mice that were followed for 24 h were compared and found to be insignificantly different. The P values were determined by the transformation Z 5 TANH 21 r for the correlation coefficients (25) .
RESULTS
SHAL Chemistry
Thirteen bidentate SHALs, 5 biotinylated and 8 DOTA conjugated containing 6 different ligands, have been synthesized in multimilligram amounts at high purity ($99%), and the DOTA-SHALs labeled with 111 In at high efficiency, specific activity, and purity ( Table 2 ). All of the SHALs electrophoresed at or near the origin and eluted using molecular sieving chromatography following 12 mL of buffer, providing evidence that the DOTA-SHALs were nearly neutral and ,5 kDa in size. Combinations of lysine and as many as 2 PEG monomers, used to vary the spacing between the ligands, did not alter binding in vitro (data not shown).
Pharmacokinetics
Although these studies were not designed to assess safety, no immediate toxicity was observed in the mice. For the bidentate SHALs (LeacPLDDo, ItPLDDo, DvLPTPLDo, and DvLPBaPLDo), the pharmacokinetics for 16 tissues were studied in groups of mice. Data are shown only for a subset of these tissues for practical reasons (Fig. 4) . Pharmacokinetics did not vary for doses of SHAL of 1 and 20 mg. Both blood and whole-body clearances of the bidentate SHALs in the xenografted mice were best fitted with a monoexponential function. Blood clearance half-times varied between 3.9 and 7.1 h, whereas whole-body clearance half-times varied between 5.5 and 20.1 h (Table 3; Fig. 4 ). In the mice, SHALs containing peptide ligands were directed to the kidney (Figs. 5 Modest uptake was seen in HLA-DR10-expressing Raji xenografts.
DISCUSSION
The incidence of NHL has increased at a rate of 3%-4% per year (26) . New therapeutic options are needed because more than two thirds of NHL patients fail to achieve longterm, disease-free survival despite multiple drug chemotherapy (27, 28) . Radioimmunotherapy has proven especially effective for NHL and compares favorably with other ''salvage'' therapies used to treat these patients; furthermore, toxicity is lower and patient acceptance is better (29) (30) (31) . To improve on these results, we designed and synthesized a series of Ab mimics for the epitopic region of HLA-DR to which Lym-1 binds (2,3). This target was selected because Lym-1 mAb has proven to be a useful carrier molecule for therapy and imaging (4, 5) . These bidentate SHALs are small molecules (#2 kDa) with associated advantages for molecular imaging and therapy. Because of their small size, they should readily penetrate vascular and tumor barriers and be excreted rapidly through the kidneys.
This series of bidentate SHALs was designed using the following rationale. A single ligand selected to bind to a site within the Lym-1 epitopic region of HLA-DR provides some selectivity but weak binding; the expectation was similar for a second ligand selected for another site within the Lym-1 epitopic region. When combined by a linker of length chosen for the distance between the 2 sites, selectivity and binding were expected to increase markedly (15, 32) . The enhanced affinity and selectivity of a bidentate SHAL designed in this manner is derived from 3 factors: (i) the distance defined by the linker allows both ligands to bind simultaneously to the sites only if the sites are separated by the correct distance; (ii) the probability that both ligands simultaneously dissociate from the target protein is substantially lower than the probability that only one will release; and, (iii) the linker prevents a dissociated ligand from diffusing away from the protein. If either ligand of the SHAL binds independently to another protein, the ligand dissociates rapidly because of its weak affinity. Thus, the bidentate SHAL binds tightly to a protein only when both ligands bind simultaneously to the protein. It is highly improbable that identical sites separated by the same distance exist on proteins other than the target protein for which the SHAL was designed. Thirteen bidentate SHALs, consisting of 2 of 6 different ligands identified to bind to either of 2 sites within the Lym-1 epitopic region, have been synthesized using a combination of lysine and PEG monomers to create the linker between the ligands. One unique feature of the synthetic scheme used to create the SHALs is that the approach allowed the attachment of biotin to the linker for in vitro assays or DOTA chelate for animal studies. Multimilligram amounts of pure SHALs having a biotin or DOTA attached to the linker were readily synthesized. Biotin made it possible to assess the binding of the SHALs to isolated HLA-DR10 protein by surface plasmon resonance and to examine their selectivity for HLA-DR-expressing live cells and tissue sections. These biotinylated, first-generation SHALs bound to HLA-DR10 protein and HLA-DR10-expressing NHL cells with nearnanomolar affinity (but not cells lacking HLA-DR10) and to sections of human lymphoma tissue (15) . The selectivity of the biotinylated SHALs for HLA-DR-expressing cells was improved by assay formats in which streptavidin converted the bidentate SHALs to multivalent species (data not shown). Once a bidentate SHAL was confirmed to be selective in vitro, a corresponding SHAL with DOTA replacing the biotin on the linker was synthesized to enable the use of radiometals for imaging and therapeutic applications. DOTASHALs were readily labeled with 111 In at high efficiency, specific activity, and purity suitable for studies in animals. For the first generation of SHALs, blood clearance was rapid, whereas body clearance was variable, depending on the ligands. Some SHALs accumulated in the liver or the kidney, demonstrating the importance of biologic considerations for ligand selection. The kidney and liver specificities of the SHALs appear to reflect the binding preferences of the individual ligands that made up these initial SHALs. This motivated us to exchange dabsylvaline for deoxycholate for site 1 and to replace leuenkephalin or triiodothyronine with benzoyl-L-arginyl-4-aminobenzoic acid for site 2. This SHAL, DvLPBaPLDo, exhibited more promising results in mice. Exchanging dabsylvaline for deoxycholate eliminated localization in the liver. Replacement of peptide-like ligands eliminated kidney uptake. Blood, body, and normal tissue clearances of this SHAL were rapid, as desired. However, xenograft clearance of this SHAL was also rapid, indicating that the off-rate of the bound SHAL needs to be improved.
This series of SHALs has shown impressive selectivity in vitro and near-nanomolar binding affinity. The length of the PEG linker for the ligands was selected on the basis of the modeled distance between the sites. Although the linker length between the ligands was assumed to be critical, linkers consisting of lysine alone or lysine with 1 or 2 PEG monomers seemed to bind to HLA-DR equally well. The results provided by these first SHAL pharmacokinetic studies, conducted in mice bearing lymphoma xenografts, have led to specific changes that improved their performance in vivo and guide additional changes to improve their effectiveness. When biologic considerations were included in the ligand selection process, the resulting SHAL, DvLPBaPLDo, showed no localization in, and rapid clearance from, normal tissues. Modest NHL tumor accumulation and the rapid kinetics of this bidentate SHAL suggest that it has potential for imaging NHL. However, the residence time of this SHAL in HLA-DR-expressing malignant Raji xenografts was not long enough to consider this SHAL for therapy. Like scFv Ab fragments, the binding affinity of the bidentate SHALs synthesized to date was not strong enough to provide prolonged tumor residence times.
To improve their potential for therapy, the SHAL affinity must be increased. This can be achieved by either of 2 approaches designed to increase the interactions between the SHAL and its protein target. One approach is to generate multidentate SHALs having more binding regions beyond those of a bidentate SHAL, thereby increasing both the affinity and the selectivity. Another approach is to generate dimeric (bis), or even trimeric, SHALs to emulate the multivalent binding of an Ab (33) . SHALs of both types continue to be very small as they have molecular weights of ,5 kDa. Consequently, rapid target penetration and localization, and normal tissue clearance, needed for high contrast in molecular imaging and high therapeutic indices in molecular therapy, are preserved.
The SHAL platform is especially attractive for molecular imaging and radiotherapy. The SHALs are easily conjugated to DOTA, a chelator suitable for a variety of metals (34) , including gadolinium for MRI, 111 In for nuclear imaging, 64 Cu for positron tomographic imaging (Fig. 7) , and therapeutic radiometals such as copper-67 and the radiolanthanides. Furthermore, the lysine in the linker provides a site for 18 F-FDG PET using established chemistry (35) .
CONCLUSION
In conclusion, SHALs have been synthesized in multimilligram amounts suitable for efficient radiometal labeling at high product yield and purity. When compared with Abs and peptides, SHALs have a shelf-life measured in years, an availability above, and cost below, that of these biologic materials, and potential for oral administration. Although individual ligands may unfavorably direct the tissue distribution of a SHAL, SHALs produced by swapping out unfavorable ligands showed markedly improved tissue distribution. Importantly, the SHAL technology established for HLA-DR can be transferred to any other protein target of interest. FIGURE 7 . To assess SHAL potential for molecular imaging, small-animal PET tomographs of a mouse in the prone position were obtained 2 h after intravenous injection of 64 Cu-labeled LePLDDo (7.4 MBq, 210 mCi; 4 mg). Coronal (A), sagittal (B), and transverse (C) sections show increased radioactivity in liver, kidney, bladder, and Raji human NHL, but not in the HBT 3477 human breast cancer xenografts on the right and left lower abdomen, respectively. A Raji xenograft was established subcutaneously in the right lower abdomen because these cells express HLA-DR10 (1) and an HBT 3477 xenograft was established subcutaneously in the left lower abdomen because these cells do not express HLA-DR10 (36) . These xenografts provided positive (Raji) and negative (HBT 3477) controls for the epitopic region of HLA-DR10 to which Lym-1 Ab binds and for which the SHALs were designed to target. microPET scans were performed on a Focus120 system (Siemens Medical Solutions USA, Inc.) and analyzed with ASIPro and the Maximum A Posteriori iterative algorithm. The mouse was anesthetized using isoflurane.
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